SCHEMBL3001902

SCHEMBL3001902

COc1ccc(-c2csc(N3CCC(S(=O)(=O)c4cc(F)ccc4C)CC3)n2)c(OC)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.57
MAPT P10636 6/20 0.46
LMNA P02545 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
USP2 O75604 1/20 0.44
RECQL P46063 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CYP1A1 P04798 2/20 0.43
CYP1B1 Q16678 2/20 0.43
SMN1; SMN2 Q16637 4/20 0.41
RAB9A P51151 4/20 0.41
REV1 Q9UBZ9 1/20 0.41
NPC1 O15118 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
NFKB1 P19838 2/20 0.39
NFKB2 Q00653 2/20 0.39
RELA Q04206 2/20 0.39
ATM Q13315 1/20 0.39
MAPK1 P28482 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010453 0.93 AR (0.50) ARMAPTLMNATDP1USP2
SCHEMBL3018691 0.91 AR (0.58) ARMAPTLMNATDP1USP2
SCHEMBL3011604 0.91 AR (0.55) ARMAPTLMNATDP1USP2
SCHEMBL3010824 0.89 AR (0.56) ARMAPTLMNATDP1USP2
SCHEMBL3016181 0.88 AR (0.58) ARMAPTLMNATDP1USP2
SCHEMBL3011213 0.88 SMN1; SMN2 (0.55) ARMAPTLMNATDP1USP2
SCHEMBL3022472 0.88 AR (0.52) ARMAPTLMNATDP1USP2
SCHEMBL3006321 0.87 AR (0.51) ARMAPTLMNATDP1USP2
SCHEMBL3002706 0.86 AR (0.56) ARMAPTLMNATDP1USP2
SCHEMBL3018230 0.86 MAPT (0.51) ARMAPTLMNATDP1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885MAPT 18/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.